Focal Treatments for Prostate Cancer
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage stance for focal ablation therapies (eg, focal laser, HIFU, cryoablation, RFA, photodynamic therapy, irreversible electroporation, magnetic nanoparticle ablation) for localized prostate cancer for Medicare Advantage and Commercial products of Blue Cross Blue Shield - Rhode Island.
No material clinical or coverage changes in this revision.
Coverage Criteria for Focal Prostate Therapies
Medicare Advantage Coverage
applies to Medicare Advantage Plans
Commercial Coverage
applies to Commercial Products
This evidence review does not cover focal brachytherapy.
If services are determined to be not medically necessary or are non-covered benefits, providers may not charge the member for those services unless the member has been informed in advance and has signed a written agreement to accept financial responsibility to continue treatment at their own expense; member benefits and eligibility are governed by the subscriber agreement, member certificate, or employer agreement and providers should contact the provider call center for member-specific information.
For Commercial Products, use of any focal therapy modality to treat patients with localized prostate cancer is considered not medically necessary because the evidence is insufficient to determine the effects of these technologies on health outcomes. Specific CPT codes listed in the policy (for example, 0655T, 0739T, and 55880) are identified as not covered or not medically necessary as indicated, and the unlisted code 55899 is provided when no assigned CPT exists.
When services are determined to be not medically necessary or are non-covered benefits, those instances are subject to the member’s benefit and eligibility rules in the subscriber agreement or employer agreement. Providers must verify member-specific coverage before providing care and, except where the member has provided a signed, informed written agreement accepting financial responsibility, such services may not be billed to the member.
Coding and Billing
| 0655T | Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging |
| 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation |
| 55880 | Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance |
| 55899 | Unlisted procedure, male genital system |
Provider Actions and Billing Guidance
Prior Authorization
Prior authorization: Not applicable at a policy level, but requirements may vary by contract. Providers must verify prior authorization requirements for the member's specific plan before scheduling services.
- Check member-specific benefit booklet or evidence of coverage for prior authorization rules
Verify Member Coverage
Benefits and eligibility vary by contract. Providers must verify member-specific coverage and benefits before providing services.
- Contact the provider call center to confirm member benefits and eligibility
Contract-Level Benefit Verification
Providers should consult the applicable benefit booklet, evidence of coverage, or subscriber agreement to determine whether services are covered under the member's contract.
- Reference member’s contract documents for coverage determinations
Denial Risk for Focal Therapies
For Medicare Advantage members, focal therapy modalities to treat localized prostate cancer are not covered; for Commercial members, these modalities are considered not medically necessary. Claims for the listed CPT codes and unlisted code 55899 are subject to denial.
Member Financial Liability for Non-covered Services
If a service is determined to be not medically necessary or is a non-covered benefit under the member’s contract, the provider may not bill the member unless the member was informed in advance and provided written agreement to accept financial responsibility.
- Obtain written informed consent from the member before performing non-covered services if the member will be financially liable
- Do not balance-bill members for services determined not medically necessary unless written agreement is obtained in advance
Documentation and Submission Guidance
Provider action: document medical necessity thoroughly in the medical record and include supporting imaging, pathology, and consult notes when submitting claims for novel or focal procedures.
- Include imaging and pathology reports with claim submission
- Attach consult notes that justify the procedure and prior treatment attempts
Background and Scope
Focal treatment aims to ablate identified prostate cancer lesions (commonly the index lesion) to reduce tumor burden while preserving surrounding glandular tissue and function. Modalities discussed include focal laser ablation, high-intensity focused ultrasound (HIFU), cryoablation, radiofrequency ablation (RFA), photodynamic therapy, irreversible electroporation, and investigational magnetic nanoparticle approaches. The available evidence is heterogeneous, lacks prospective comparative trials, and is insufficient to demonstrate improved net health outcomes.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.